Drug Trial Radar · NCT03633799
Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,620
Actual
Start
Aug 22, 2018
Primary completion
Sep 22, 2022
Study completion Sep 22, 2027
Sponsor
- Lead sponsor
- Sebela Women's Health Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- Aug 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To assess the contraceptive efficacy (prevention of pregnancy) of VeraCept
Conditions
- Women at Risk for Pregnancy
Interventions
VeraCeptDrug
VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
Primary outcomes
What the sponsor says the trial is designed to measure.
- Contraceptive Efficacy Through 3 Years of UseTime frame: 3 years
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
MomDoc Women's Health Research
Scottsdale, Arizona
Copperstate OB/GYN Associates
Tucson, Arizona
Essential Access Health
Berkeley, California
Essential Access Health
Los Angeles, California
Empire Clinical Research
Pomona, California
University of California, Davis Health System
Sacramento, California
M3 Wake Research (formerly Women's Health Care Research)
San Diego, California
M3 Wake Research (formerly Medical Center for Clinical Research)
San Diego, California
Stanford University, Medical Center, Obstetrics and Gynecolocy
Stanford, California
Velocity Clinical Research (formerly Downtown Women's Health Care)
Englewood, Colorado
Altus Research, Inc
Lake Worth, Florida
Emory University School of Medicine
Atlanta, Georgia
Soapstone Center for Clinical Research
Decatur, Georgia
Clinical Research Prime
Idaho Falls, Idaho
Women's Health Advantage
Fort Wayne, Indiana
Indiana University
Indianapolis, Indiana
Praetorian Pharmaceutical Research
Marrero, Louisiana
University of Michigan Von Voigtlander Women's Hospital
Ann Arbor, Michigan
Planned Parenthood North Central States - Minneapolis
Minneapolis, Minnesota
Planned Parenthood Great Rivers (formerly Planned Parenthood of the St. Louis Region and Southwest Missouri)
Manchester, Missouri
Rex Garn Mabey Jr., MD
Las Vegas, Nevada
Capital Health Lawrence OBGYN Research (formerly Lawrence OB/Gyn Clinical Research)
Lawrenceville, New Jersey
Columbia University Medical Center, Division of Family Planning
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati/Reproductive Medicine Research
Cincinnati, Ohio
The Ohio State University Ob/Gyn Research Office
Columbus, Ohio
OHSU Women's Health Research Unit
Portland, Oregon
University of Pennsylvania/Penn Family Planning and Pregnancy Loss Center
Philadelphia, Pennsylvania
Clinical Research of Philadelphia
Philadelphia, Pennsylvania
Magee-Womens Hospital, Center for Family Planning Research
Pittsburgh, Pennsylvania
Medical Research South, LLC
Charleston, South Carolina
Chattanooga Medical Research
Chattanooga, Tennessee
The Jackson Clinic, PA
Jackson, Tennessee
Advanced Research Associates
Corpus Christi, Texas
Advances In Health
Pearland, Texas
Wasatch Clinical Research
Salt Lake City, Utah
University of Utah Healthcare Health Sciences Center
Salt Lake City, Utah
Tidewater Physicians for Women
Norfolk, Virginia
Eastern Virginia Medical
Norfolk, Virginia
Seattle Clinical REsearch Center (formerly Seattle Women's Health)
Seattle, Washington
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.